Your browser doesn't support javascript.
loading
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
Canti, Lorenzo; Humblet-Baron, Stéphanie; Desombere, Isabelle; Neumann, Julika; Pannus, Pieter; Heyndrickx, Leo; Henry, Aurélie; Servais, Sophie; Willems, Evelyne; Ehx, Grégory; Goriely, Stanislas; Seidel, Laurence; Michiels, Johan; Willems, Betty; Liston, Adrian; Ariën, Kevin K; Beguin, Yves; Goossens, Maria E; Marchant, Arnaud; Baron, Frédéric.
Afiliação
  • Canti L; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
  • Humblet-Baron S; Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium.
  • Desombere I; SD Infectious Diseases in Humans, Sciensano, 642 Engelandstraat, 1180, Ukkel, Belgium.
  • Neumann J; Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium.
  • Pannus P; SD Infectious Diseases in Humans, Sciensano, 642 Engelandstraat, 1180, Ukkel, Belgium.
  • Heyndrickx L; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000, Antwerp, Belgium.
  • Henry A; Division of Hematology, Department of Medicine, CHU of Liège, Liège, Belgium.
  • Servais S; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
  • Willems E; Division of Hematology, Department of Medicine, CHU of Liège, Liège, Belgium.
  • Ehx G; Division of Hematology, Department of Medicine, CHU of Liège, Liège, Belgium.
  • Goriely S; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
  • Seidel L; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.
  • Michiels J; Department of Biostatistics, University Hospital of Liège, Liège, Belgium.
  • Willems B; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000, Antwerp, Belgium.
  • Liston A; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000, Antwerp, Belgium.
  • Ariën KK; Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium.
  • Beguin Y; Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, UK.
  • Goossens ME; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000, Antwerp, Belgium.
  • Marchant A; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
  • Baron F; Division of Hematology, Department of Medicine, CHU of Liège, Liège, Belgium.
J Hematol Oncol ; 14(1): 174, 2021 10 24.
Article em En | MEDLINE | ID: mdl-34689821
BACKGROUND: Factors affecting response to SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients remain to be elucidated. METHODS: Forty allo-HCT recipients were included in a study of immunization with BNT162b2 mRNA vaccine at days 0 and 21. Binding antibodies (Ab) to SARS-CoV-2 receptor binding domain (RBD) were assessed at days 0, 21, 28, and 49 while neutralizing Ab against SARS-CoV-2 wild type (NT50) were assessed at days 0 and 49. Results observed in allo-HCT patients were compared to those obtained in 40 healthy adults naive of SARS-CoV-2 infection. Flow cytometry analysis of peripheral blood cells was performed before vaccination to identify potential predictors of Ab responses. RESULTS: Three patients had detectable anti-RBD Ab before vaccination. Among the 37 SARS-CoV-2 naive patients, 20 (54%) and 32 (86%) patients had detectable anti-RBD Ab 21 days and 49 days postvaccination. Comparing anti-RBD Ab levels in allo-HCT recipients and healthy adults, we observed significantly lower anti-RBD Ab levels in allo-HCT recipients at days 21, 28 and 49. Further, 49% of allo-HCT patients versus 88% of healthy adults had detectable NT50 Ab at day 49 while allo-HCT recipients had significantly lower NT50 Ab titers than healthy adults (P = 0.0004). Ongoing moderate/severe chronic GVHD (P < 0.01) as well as rituximab administration in the year prior to vaccination (P < 0.05) correlated with low anti-RBD and NT50 Ab titers at 49 days after the first vaccination in multivariate analyses. Compared to healthy adults, allo-HCT patients without chronic GVHD or rituximab therapy had comparable anti-RBD Ab levels and NT50 Ab titers at day 49. Flow cytometry analyses before vaccination indicated that Ab responses in allo-HCT patients were strongly correlated with the number of memory B cells and of naive CD4+ T cells (r > 0.5, P < 0.01) and more weakly with the number of follicular helper T cells (r = 0.4, P = 0.01). CONCLUSIONS: Chronic GVHD and rituximab administration in allo-HCT recipients are associated with reduced Ab responses to BNT162b2 vaccination. Immunological markers could help identify allo-HCT patients at risk of poor Ab response to mRNA vaccination. TRIAL REGISTRATION: The study was registered at clinicaltrialsregister.eu on 11 March 2021 (EudractCT # 2021-000673-83).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Anticorpos Neutralizantes / Vacinas contra COVID-19 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Revista: J Hematol Oncol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Anticorpos Neutralizantes / Vacinas contra COVID-19 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Revista: J Hematol Oncol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Bélgica